Literature DB >> 19864026

Involvement of the c-jun N-terminal kinases JNK1 and JNK2 in complement-mediated cell death.

Dana Gancz1, Natalie Donin, Zvi Fishelson.   

Abstract

Cell death and survival signals activated by the complement membrane attack complex C5b-9 play important roles in complement-associated diseases and in antibody-based cancer therapy. Here, we investigated the involvement of the JNK mitogen-activated protein kinase in C5b-9-induced cell lysis. Necrotic-type cell death regulation by JNK1 and JNK2 was selectively studied in mouse fibroblasts and human K562, HeLa and 293T cells. C5b-9 induced higher JNK activation than C5b-8. Pretreatment with a JNK inhibitor reduced cell sensitivity to complement-mediated lysis. KO cells deficient in either JNK1 or JNK2 were less sensitive to lysis than WT cells. This correlated with lower C3 and C5b-9 deposition on KO cells. Furthermore, silencing of JNK1 or JNK2 expression by RNA interference decreased cell lysis by complement. Reconstitution of JNK2 into JNK2-/- cells and over expression of JNK2 in WT cells increased C3 and C5b-9 deposition as well as cell sensitivity to complement-mediated lysis. Pretreatment of cells with the phosphotyrosine phosphatase inhibitor phenylarsine oxide increased JNK activation and JNK-dependent complement-mediated necrotic death of WT and JNK2-/- KO cells but not of JNK1-/- KO cells. The JNK inhibitor and PAO had no effect on complement-mediated lysis in cells lacking Bid, suggesting involvement of Bid in the JNK lytic pathway. Our results demonstrate that complement C5b-9 induce a JNK/Bid-dependent and JNK-independent necrotic cell death. Both JNK1 and JNK2 have cytotoxic potential, however JNK2 is the primary signal transducer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19864026     DOI: 10.1016/j.molimm.2009.09.016

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  13 in total

Review 1.  JNK signaling as a target for anticancer therapy.

Authors:  Kamal S Abdelrahman; Heba A Hassan; Salah A Abdel-Aziz; Adel A Marzouk; Atsushi Narumi; Hiroyuki Konno; Mohamed Abdel-Aziz
Journal:  Pharmacol Rep       Date:  2021-03-12       Impact factor: 3.024

2.  Combination Therapy with Low-Dose IVIG and a C1-esterase Inhibitor Ameliorates Brain Damage and Functional Deficits in Experimental Ischemic Stroke.

Authors:  Xinzhi Chen; Thiruma V Arumugam; Yi-Lin Cheng; Jong-Hwan Lee; Srinivasulu Chigurupati; Mark P Mattson; Milan Basta
Journal:  Neuromolecular Med       Date:  2018-01-03       Impact factor: 3.843

Review 3.  Membrane attack by complement: the assembly and biology of terminal complement complexes.

Authors:  Cosmin A Tegla; Cornelia Cudrici; Snehal Patel; Richard Trippe; Violeta Rus; Florin Niculescu; Horea Rus
Journal:  Immunol Res       Date:  2011-10       Impact factor: 2.829

4.  Caveolin-1 and dynamin-2 are essential for removal of the complement C5b-9 complex via endocytosis.

Authors:  Oren Moskovich; Lee-Or Herzog; Marcelo Ehrlich; Zvi Fishelson
Journal:  J Biol Chem       Date:  2012-04-23       Impact factor: 5.157

5.  Increased JNK1 signaling pathway is responsible for ABCG2-mediated multidrug resistance in human colon cancer.

Authors:  Ming Ming Zhu; Jin Lu Tong; Qi Xu; Fang Nie; Xi Tao Xu; Shu Dong Xiao; Zhi Hua Ran
Journal:  PLoS One       Date:  2012-08-01       Impact factor: 3.240

6.  Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers.

Authors:  Anouk Emadali; Sophie Rousseaux; Juliana Bruder-Costa; Claire Rome; Samuel Duley; Sieme Hamaidia; Patricia Betton; Alexandra Debernardi; Dominique Leroux; Benoit Bernay; Sylvie Kieffer-Jaquinod; Florence Combes; Elena Ferri; Charles E McKenna; Carlo Petosa; Christophe Bruley; Jérôme Garin; Myriam Ferro; Rémy Gressin; Mary B Callanan; Saadi Khochbin
Journal:  EMBO Mol Med       Date:  2013-07-04       Impact factor: 12.137

7.  Receptor-Interacting Protein Kinases 1 and 3, and Mixed Lineage Kinase Domain-Like Protein Are Activated by Sublytic Complement and Participate in Complement-Dependent Cytotoxicity.

Authors:  Michal Lusthaus; Niv Mazkereth; Natalie Donin; Zvi Fishelson
Journal:  Front Immunol       Date:  2018-02-23       Impact factor: 7.561

Review 8.  Complement C5b-9 and Cancer: Mechanisms of Cell Damage, Cancer Counteractions, and Approaches for Intervention.

Authors:  Zvi Fishelson; Michael Kirschfink
Journal:  Front Immunol       Date:  2019-04-10       Impact factor: 7.561

9.  JNK2 is activated during ER stress and promotes cell survival.

Authors:  M Raciti; L V Lotti; S Valia; F M Pulcinelli; L Di Renzo
Journal:  Cell Death Dis       Date:  2012-11-22       Impact factor: 8.469

10.  Cooperation between Hsp90 and mortalin/GRP75 in resistance to cell death induced by complement C5b-9.

Authors:  Perri Rozenberg; Lea Ziporen; Dana Gancz; Moran Saar-Ray; Zvi Fishelson
Journal:  Cell Death Dis       Date:  2018-02-02       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.